The changing face of chemotherapy in colorectal cancer by Waters, J & Cunningham, D
Cytotoxic chemotherapy for colorectal cancer has undergone a
period of dramatic development over the course of the last 5 years.
Four distinct classes of drug with activity in this disease are now
available, and the current challenge is to establish the best way to
use these agents, either in sequence or in combination, for the
benefit of patients. This review aims to summarize the data
relating to the newer agents and to propose directions for future
research. 
DRUGS TARGETING THYMIDYLATE SYNTHASE 
5-fluorouracil (5-FU) has established single-agent activity in
advanced colorectal cancer. Its main intracellular target is
thymidylate synthase, which is inhibited by the active metabolite of
5-FU, 5-fluorodeoxyuridine monophosphate (FdUMP) (Figure 1).
The lack of alternative agents until recent years has fuelled extens-
ive research into the biochemical modulation of 5-FU and alterna-
tive methods of delivery, primarily based on continuous infusion
of the drug. Many individual clinical trials have demonstrated
enhanced response rates when 5-FU is co-administered with
folinic acid (calcium leucovorin). However a significant survival
benefit has been more difficult to establish. Indeed a meta-analysis
of nine trials showed no survival advantage for folinic acid-
modulated 5-FU over 5-FU alone (Advanced Colorectal Cancer
Meta-Analysis Project, 1992). Similarly, continuous infusion of 5-
FU using a variety of different schedules also enhances response
rates over bolus delivery. A meta-analysis of seven randomized
trials addressing this question showed a small but statistically
significant improvement in median survival for 5-FU infusion
over 5-FU bolus (12.1 vs 11.3 months, P = 0.039). Haematological
toxicity was also significantly less common with 5-FU infusion,
underlining the improved therapeutic ratio provided by this
approach (Meta-analysis Group In Cancer, 1998). 
Drawing on the experience gained with 5-FU infusion, two new
avenues of drug development have been explored. The direct
thymidylate synthase (TS) inhibitors are a group of rationally
designed molecules that compete with folinic acid for binding to
TS (Figure 1). Intracellular polyglutamation of some of these
compounds leads to their retention within the cell, and hence
prolonged inhibition of TS. Raltitrexed, the lead agent in this
class, has been the subject of extensive clinical evaluation. Its
efficacy at the established dose of 3 mg m− 2 every 3 weeks appears
comparable to either bolus or infused regimens of 5-FU/folinic
acid (Cunningham et al, 1996; Harper, 1997; Pazdur and Vincent,
1997; Maughan et al, 1999) (Table 1). However, one of the four
randomized controlled trials conducted to date demonstrated a
significantly inferior median survival with raltitrexed compared
with the Mayo regimen of bolus 5-FU and folinic acid given daily
  5 every 4–5 weeks (9.7 vs 12.7 months, P = 0.011) (Pazdur and
Vincent, 1997). The toxicity profile of raltitrexed is different to
that of folinic acid-modulated 5-FU, producing significantly less
mucositis and leucopenia, but a greater incidence of elevated
transaminases. Of some concern, one study reported a toxic death
rate of 5.6% associated with raltitrexed (Maughan et al, 1999). A
significant number of these patients had mild–moderate renal
impairment, which appears to be an important determinant of
severe toxicity with this agent. We would currently recommend
assessing renal function prior to administration of raltitrexed,
and to proceed only if the creatinine clearance is greater than
65 ml min− 1..
Other direct TS inhibitors have entered clinical evaluation, but
have not as yet been compared with established regimens in
randomized trials. One such, nolatrexed is a lipophilic molecule,
entering cells by diffusion and lacking a requirement for the
reduced folate carrier for transport. It also lacks a glutamate side-
chain and is therefore not polyglutamated. Thus it has the potential
to overcome some of the resistance mechanisms observed with
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Figure 1 Direct and indirect thymidylate synthase inhibitors many other compounds in this class. Phase I trials have established
nausea and vomiting as the dose-limiting toxicities of oral nola-
trexed (Hughes et al, 1999; Jodrell et al, 1999), and phase II
studies investigating this agent in a number of solid tumours
including colorectal cancer are underway. 
A second approach to the problem of achieving continuous inhi-
bition of TS without the requirement for protracted intravenous
infusion of 5-FU has been the development of orally bioavailable
fluoropyrimidines. 5-FU itself has erratic oral bioavailability,
precluding oral administration. This problem has been overcome
by the use of prodrugs of 5-FU that are well absorbed from
the gastrointestinal tract and enzymatically converted to 5-FU
in the liver or within the tumour itself. UFT is a combination of
the prodrug tegafur and uracil in a 1:4 molar ratio. Uracil is a
reversible inhibitor of the enzyme dihydropyrimidine dehydroge-
nase, which is responsible for the catabolism of 5-FU. UFT
300–350 mg m 2 day 1 given in combination with oral folinic acid
150 mg m 2 day 1 for 28 days followed by a 7-day rest produced a
response rate of 42% in a phase II study in 45 chemotherapy-naive
patients (Pazdur et al, 1994). Grade III diarrhoea was seen in five
out of seven patients treated at the higher dose level but only in
four of 38 at the reduced dose, which was therefore recommended
for further evaluation. This combination has been compared with
intravenous bolus administration of 5-FU/folinic acid in two
randomized clinical trials involving 1196 patients in total (Table 2).
In the North American trial, the standard Mayo Clinic regimen
was used as the control arm (Pazdur et al, 1999), whereas in the
European trial the modified Mayo regimen was used, in which
bolus 5-FU and folinic acid are administered daily for 5 consecu-
tive days every 5 weeks (Carmichael et al, 1999). The response
rates to UFT/folinic acid were 12% in these studies, and were
statistically equivalent to those produced by the Mayo regimens.
The median overall survival duration was also equivalent in the
two arms but the North American study showed a significantly
poorer median time to disease progression in the UFT/folinic
acid arm. Severe toxicity was seen less frequently with the oral
formulation, particularly with regard to neutropenia and infection,
although hyperbilirubinaemia was more common. 
Capecitabine is a fluoropyrimidine carbamate that is activated in
three enzymatic steps. The final activating enzyme is the tumour-
associated angiogenesis factor thymidine phosphorylase, thus
reducing exposure of normal tissues to the active metabolite. In a
phase II study comparing three schedules of administration in 109
chemotherapy-naive patients with advanced CRC, response rates of
24% were seen, with one third of patients experiencing grade III
toxicity. Median time to progression was 30 weeks with the optimal
schedule of 2510 mg m 2 day 1 given intermittently. Capecitabine
has also been evaluated in two randomized, controlled trials (Table
2) (Cox et al, 1999; Twelves et al, 1999). The Mayo regimen was
also selected as the control arm in these studies. Tumour response
rates were higher in the capecitabine arms in both studies (27% vs
18% and 23% vs 16%, both P ≤ 0.02), and progression-free
survival and overall survival were equivalent between the two
arms. The toxicity profile of capecitabine was broadly favourable
in comparison with the Mayo regimen, producing less neutropenia
and mucositis, although palmar-plantar erythema was more
common with the oral compound. 
It is clear from the data discussed above that several approaches
to TS inhibition have been applied successfully to patients with
advanced colorectal cancer. As might be expected, the activity of
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Table 1 Randomized trials comparing raltitrexed with 5-fluorouracil regimens 
Trial Cunningham et al,  Harper, 1997 Pazdur and Vincent,  Maughan et al, 
1996 1997 1999 
Arm Raltitrexed 5-FU +  Raltitrexed 5-FU +  Raltitrexed 5-FU +  Raltitrexed Lokich de Gramont 
LDFA LDFA LDFA
Patients (n) 223 216 230 222 199 179 301 301 303 
Response rate (%) 19.3 16.7 18.6 18.1 14.3 15.2 20 26 24 
Median overall  10.1 10.2 10.9  12.3 9.7 12.7 10 10 10 
survival (months)
P value for survival 0.42 0.197 0.01 Not significant 
5-FU + LDFA = Mayo Clinic regimen of bolus 5-FU plus low-dose folinic acid days 1–5 every 4–5 weeks; Lokich = protracted venous infusion 5-FU; de Gramont
= folinic acid infusion followed by 5-FU bolus and 22-h infusion on two consecutive days every 2 weeks; Raltitrexed = 3 mg m− 2 iv bolus every 3 weeks.
Table 2 Randomized trials comparing two oral fluoropyrimidines with bolus 5-FU/folinic acid 
Trial Twelves et al, 1999 Cox et al, 1999 Pazdur et al, 1999 Carmichael et al, 1999 
Arm Capecitabine 5-FU +  Capecitabine 5-FU + UFT + FA 5-FU + UFT + FA 5-FU +  
LDFAa LDFAa LDFAb LDFAa
Patients (n) 301 301 302 303 816 380 
Response rate (%) 26.6 17.9 23.2 15.5 12  15 11 9 
P value for response 0.013 0.02 0.232 0.593 
Median PFS (months) 5.5 4.9 4.4 5.1 3.5c 3.8c 3.4c 3.3c
P value for PFS 0.67 Not significant 0.011 0.591 
Median overall survival  13.71 3.0 Not reported 12.4 13.4 12.2 11.9 
(months)
P value for survival 0.68 – Not significant 0.682 
Capecitabine = 2500 mg m− 2 day− 1 for 2 weeks out of each 3-week cycle; UFT 300 mg m− 2 day− 1 and folinic acid 75 or 90 mg day− 1 for 28 days out of every 
35-day cycle; 5-FU + LDFA = Mayo clinic regimen of bolus 5-FU plus low-dose folinic acid days 1–5 every 4a or 5b weeks; cTime to progression quoted each approach is similar, although differences in toxicity profile
and ease of administration have been demonstrated. It is perhaps
significant that most of the randomized trials performed with the
newer agents have employed the relatively toxic Mayo regimen as
the control arm, possibly enhancing the appearance of their toler-
ability. However, the advantage of being able to dispense with
indwelling venous catheters is substantial, and is likely to lead to
the gradual replacement of 5-FU as the fluoropyrimidine of
choice. The similarity of the mechanism of action of these agents
means that activity in 5-FU-resistant patients is likely to be modest
at best. This has been borne out in the few studies to address this
question to date (Farrugia et al, 1998). Thus the availability of new
agents with distinct intracellular targets was required to enhance
survival rates for patients with this disease. 
IRINOTECAN 
Irinotecan (CPT-11, Campto) is a semi-synthetic camptothecin
derivative that inhibits DNA topoisomerase I. It has been shown to
have activity against colorectal cancer cell lines in vitro, and proved
manageable in phase I clinical trials using a variety of schedules.
The most important toxicities associated with its use are diarrhoea,
neutropenia, nausea, alopecia, cholinergic syndrome and asthenia.
The incidence of severe diarrhoea is significantly reduced by
the early and aggressive use of loperamide, and the cholinergic
syndrome is prevented in the majority of patients by premedication
with anticholinergic agents. The occurrence of severe diarrhoea
concomitantly with severe neutropenia is, however, life-threatening,
requiring immediate hospital admission and the institution of
supportive measures. During phase II development, irinotecan was
found to show activity both in chemotherapy-naive and in 5-FU-
resistant patients, and was therefore initially formally evaluated in
randomized trials as a second-line treatment. In order to quantify
the impact of second-line irinotecan therapy on survival and quality
of life, a prospective multicentre randomized phase III clinical trial
was designed to compare irinotecan with best supportive care in
this setting (Cunningham et al, 1998). 279 patients were random-
ized on a 2:1 basis. Hence 189 patients were randomized to receive
irinotecan 350 mg m− 2 every 3 weeks for up to eight cycles, and 90
patients were randomized to supportive care alone. Patients were
required to have documented progression of metastatic colorectal
cancer while on 5-FU or within 6 months of the last 5-FU infusion,
and to have had no more than two prior 5-FU regimens for
metastatic disease. 71% of patients had tumour-related symptoms.
With a median follow-up of 13 months, the median overall survival
was significantly better in the irinotecan group (9.2 vs 6.5 months,
P= 0.0001). 1-year survival was 2.6 times greater in the irinotecan
group (36.2% irinotecan vs 13.8% supportive care). The survival
advantage adjusted for prognostic factors remained highly signifi-
cant. Grade III–IV toxicity in the irinotecan arm comprised
neutropenia in 22% of patients (3% with febrile neutropenia), diar-
rhoea in 22%, vomiting in 14%, and mucositis in 2% of patients.
Severe asthenia and pain occurred more frequently in the
supportive care arm. Survival without Performance Status (PS)
deterioration, without weight loss >5% and pain-free survival were
significantly better in the irinotecan group (P = 0.0001, 0.018 and
0.003, respectively). Global health status assessed by the European
Organization for Research and Treatment of Cancer (EORTC)
QLQ-C30 quality of life questionnaire was also significantly better
in the irinotecan arm (P <0.001), and time to deterioration of
quality of life was longer in this group (P <0.002). This study
clearly demonstrated the advantage of irinotecan over no specific
treatment in good performance status patients following 5-FU
failure, both in overall survival and in quality of life. 
A second large multicentre phase III trial compared irinotecan
with one of three 5-FU infusion regimens (protracted venous infu-
sion 5-FU, weekly high-dose 24-h infusion 5-FU with folinic acid or
the de Gramont regimen of bimonthly folinic acid and 5-FU bolus
plus 48-h infusion, depending on local practice). Patients had
documented progressive disease within 3 months of adjuvant 5-FU
or their first palliative 5-FU regimen (Rougier et al, 1998). 157
patients were randomized. 62% of patients had been previously
treated with a bolus 5-FU regimen and 38% had received a prior
infused 5-FU regimen. 13% had only previously received adjuvant
5-FU. With a median follow-up of 15 months, median survival was
significantly longer in the irinotecan arm (10.8 months vs 8.5
months; P = 0.04), with a 1-year survival 1.4 times greater than in
the 5-FU infusion group (44.8% vs 32.4% respectively). Progression-
free survival was also significantly prolonged in the irinotecan group,
with a median of 4.2 months compared with 2.9 months in the 5-FU
group (P = 0.029). Quality of life was maintained in both groups, and
toxic effects were similar, although diarrhoea and vomiting were more
common in the irinotecan arm. Once again, in multivariate analysis,
treatment arm remained a significant favourable prognostic factor for
survival. Taken together, these two studies clearly established a role
for irinotecan in patients with 5-FU-refractory advanced colorectal
cancer who are sufficiently fit for treatment. 
Two multicentre randomized controlled trials have evaluated the
addition of irinotecan to standard bolus or infused regimens of
5-FU and folinic acid as first-line therapy for advanced colorectal
cancer (Table 3). The results of these studies formed the basis of a
submission to the Oncologic Drugs Advisory Committee of the
Food and Drug Administration (FDA) of the USA, which
approved irinotecan for the first-line treatment of advanced
colorectal cancer. The first study (Douillard et al, 2000),
conducted in Europe and South Africa, evaluated the addition of
irinotecan to one of two infused 5-FU/folinic acid regimens: the de
Gramont regimen, or a weekly regimen of folinic acid and 24-h
5-FU infusion (the regimen to be used was selected prior to
commencement of the study by each participating centre). 385
patients were randomized in the study. There was a statistically
significant difference in objective response rate (34.8% vs 21.9%,
P = 0.005), overall survival (17.4 vs 14.1 months, P = 0.031), and
time to progression (6.7 vs 4.4 months, P < 0.001) in favour of the
irinotecan-containing arm. Toxicity was increased in patients
treated with irinotecan. Diarrhoea, neutropenia and asthenia were
increased in frequency and severity compared with patients
receiving 5-FU/folinic acid alone, and one toxic death occurred in
the irinotecan group as a result of septic shock and diarrhoea.
However, quality of life scores were similar in the two arms, and
time to deterioration of quality of life was longer in the irinotecan
arm. The second study was conducted in the USA and involved
683 patients (Saltz et al, 1999, 2000). Randomization was between
three treatment arms: the Mayo regimen of bolus 5-FU/folinic
acid; weekly irinotecan alone; weekly irinotecan plus bolus 5-FU
and folinic acid for 4 of every 6 weeks. However the primary
analysis compared only the irinotecan/5-FU/folinic acid and
5-FU/folinic acid arms. An updated analysis of this trial presented
at the annual meeting of the American Society of Clinical
Oncology in May 2000 has shown improved response rates
(39.4% vs 20.8%, P < 0.0001), time to progression (7.0 vs 4.3
months, P = 0.004) and overall survival (14.8 vs 12.6 months, 
Chemotherapy in colorectal cancer 3
British Journal of Cancer (2001) 84(1), 1–7 © 2001 Cancer Research CampaignP = 0.042) associated with the combination treatment. The combi-
nation of 5-FU and irinotecan produced more grade III or IV diar-
rhoea, asthenia and alopecia than the Mayo schedule. However, it
was associated with a similar incidence of severe neutropenia and
fewer episodes of febrile neutropenia and mucositis. Toxic death
rates were less than 2%, and were similar in the three arms. This
study also confirmed that quality of life was similar between treat-
ment arms. A combined analysis of the results from these two
trials showed hazard ratios for time to disease progression of 0.67
(P < 0.001) and survival of 0.79 (P < 0.009) in favour of the
combination treatment (Saltz et al, 2000). 
OXALIPLATIN 
Oxaliplatin is a third-generation platinum complex with single-
agent activity in colorectal cancer. Importantly, synergy is demon-
strated between oxaliplatin and 5-FU both in vitro and in
chemotherapy-naive patients. There have been no randomized
trials of oxaliplatin-containing regimens as second-line therapy in
5-FU-resistant colorectal cancer reported to date. However, a
number of phase II trials have demonstrated the feasibility of
combining oxaliplatin with various 5-FU/folinic acid regimens in
this setting, including the modified Mayo regimen (Van Cutsem
et al, 1999) bimonthly 48-h infusion regimens (de Gramont et al,
1997; Maindrault-Goebel et al, 1998,1999), and weekly high-
dose 24-h infusion (Janinis et al, 1999; Van Cutsem et al, 1999).
Response rates have ranged from 11–46%, with median survival
up to 17 months, suggesting that such combinations may have a
useful role. The contribution of 5-FU to the efficacy of these regi-
mens in patients with 5-FU-resistant disease has been called into
question. Some of the more recent trials have demonstrated
response rates similar to those produced by single-agent oxali-
platin (Van Cutsem et al, 1999). 
Oxaliplatin plus 5-FU/folinic acid has been compared with
5-FU/folinic acid alone as first-line treatment for advanced
colorectal cancer in two large randomized phase III trials
(Table 3). 420 patients were randomized to receive a regimen of
folinic acid and 5-FU bolus plus 24-h infusion on two consecutive
days every 2 weeks plus or minus oxaliplatin 85 mg m− 2 every 2
weeks (de Gramont et al, 2000). Median progression-free survival
was superior in the oxaliplatin arm (9 months vs 6.2 months, P=
0.0003). Median overall survival also showed a trend to superi-
ority in the oxaliplatin arm (16.2 months vs 14.7 months, P =
0.12). Cross-over from the 5-FU/folinic acid arm to the oxali-
platin/5-FU/folinic acid arm following progression may account
for the smaller difference in median survival seen between the two
arms. Furthermore, when subjected to multivariate analysis,
randomization to the oxaliplatin-containing arm was a statistically
significant favourable prognostic factor for survival. Quality of
life was also evaluated in this study. Patients randomized to
receive oxaliplatin had a significantly prolonged survival without
20% (P = 0.0039), or 40% (P = 0.0004) deterioration in quality of
life. In the second trial, 200 patients received the same
chronomodulated 5-day infusion of 5-FU (700 mg m− 2 day− 1) plus
folinic acid (300 mg m− 2 day− 1) with or without oxaliplatin
(125 mg m− 2 day 1), with courses repeated every 3 weeks. The
median progression-free survival was 7.9 months in the oxaliplatin
arm, and 4.3 months in the control arm (P= 0.05). Median overall
survival showed no significant difference between arms (17.6
months oxaliplatin, 19.4 months control, P = 0.82) (Giacchetti
et al, 1997). An analysis of the use of second-line chemotherapy
and surgery for metastases in the two arms of this trial showed that
both of these treatment modalities were more commonly
employed in the control arm, and were likely to account for the
lack of a significant survival benefit in the oxaliplatin arm
(Giacchetti et al, 1998). 
COMBINATIONS OF IRINOTECAN AND
OXALIPLATIN 
The differing mechanism of action and non-overlapping dose-
limiting toxicity profiles of these two agents provides a good
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Table 3 Randomized trials of combination chemotherapy in the first-line treatment of advanced colorectal cancer 
Trial Treatment Patients (n) Response  P value Median TTP  P value Median OS P value 
arm rate (%) (months) (months)
V307   Irinotecan +  198 35 <0.005 6.7 0.001 17.4 0.032 
Douillard et al, 5-FU/FAa
2000
5-FU/FAa 187 22 4.4 14.1 
0038 Saltz  Irinotecan +   231 39 <0.001 7.0 0.004 14.8 0.042 
et al, 1999 5-FU/FAb
5-FU/FAb 226 21 4.3 12.6 
Irinotecan 226 18 – 4.2 – 12.0 – 
2961   Oxaliplatin +  100 34 0.001 8.3 0.0003 17.4 0.58 
Giacchetti et al,  5-FU/FAc
1997
5-FU/FAc 100 12 4.2 19.2 
2962 Oxaliplatin  +  210 49 0.001 9.0 0.0003 16.2 0.12 
de Gramont  5-FU/FAa
et al, 2000
5-FU/FAa 210 22 6.2 14.7 
Ross et al,  Mitomycin C  98 54 0.024 7.9 0.033 14.0 ns 
1997 + PVI 5-FU
PVI 5-FU 97 38 5.4 12.7
ade Gramont regimen of 5-FU and folinic acid; bModified Mayo regimen; cChronomodulated infusion of 5-FU and folinic acid. See text for details of regimens. rationale for their use in combination. This has been investigated
in a number of phase I/II trials from which some preliminary
results are available. The combination appears manageable and
effective in patients with 5-FU-refractory disease using a variety
of schedules including weekly (Kemeny et al, 2000), 2-weekly
(Goldwasser et al, 1999; Wasserman et al, 1999) and 3-weekly
dosing (Wasserman et al, 1999). Reported response rates have
ranged from 17–64% in this patient population. 
MITOMYCIN C 
Mitomycin C has been in use for the treatment of metastatic
colorectal cancer for many years with response rates of 0–30%.
In a multicentre randomized trial including 200 patients with
chemotherapy-naive disease, the addition of mitomycin C to a
protracted venous infusion of 5-FU improved response rates (54%
vs 38% P = 0.024), and median failure-free survival (7.9 vs 5.4
months, P = 0.033) compared with protracted venous infusion 5-FU
alone (Table 3) (Ross et al, 1997). However, there were no overall
survival differences between the two arms. The combination
produced higher rates of haematological toxicity, and particularly
thrombocytopenia, but non-haematological toxicity was similar in
the two arms. Haemolytic uraemic syndrome was seen in two
patients treated at the initial mitomycin C dose of 10 mg mg− 2 every
6 weeks, but in no patients treated at a reduced dose of 7 mg m− 2. 
CONCLUSIONS 
The debate on the management of advanced colorectal cancer
has moved on from the question of whether to use palliative
chemotherapy to the question of which drugs to use, and in what
sequence. A major issue for current debate is whether to use drugs
in sequence or in combination. As yet no completed clinical trials
have addressed this question fully. However, a number of clues are
available from the studies outlined above. Firstly, it is clear that
patients who are fit enough to receive second-line chemotherapy
after 5-FU failure will derive benefit from it. This has been demon-
strated unequivocally in the case of irinotecan, with two random-
ized clinical trials providing supportive data. It is also likely to be
true for oxaliplatin, although formal randomized trials testing this
hypothesis have not been reported as yet. It is much less probable
that the oral fluoropyrimidines or the direct thymidylate synthase
inhibitors will provide significant benefits in this setting, although
different mechanisms of resistance to some of these agents may
allow scope for their use in this patient population. 
A potential drawback of the sequential approach is that a propor-
tion of patients will not be fit enough for second-line chemotherapy
after 5-FU failure due to rapid disease progression, and may there-
fore be denied exposure to an agent to which their disease may be
sensitive. The use of combination chemotherapy as first-line treat-
ment may overcome this problem. This is suggested by the results
of the two trials comparing irinotecan plus 5-FU/folinic acid with 5-
FU/folinic acid alone. Despite the fact that 31% and 50% of patients
in the latter arm of the two trials went on to receive second-line
irinotecan, a survival benefit for the combination chemotherapy was
observed (Saltz et al, 1999; Douillard et al, 2000). The lack of a
similar survival advantage in the two trials evaluating oxaliplatin
plus 5-FU/folinic acid in the first-line setting may reflect the better
performance status of the patients enrolled in these trials, leading to
a greater proportion of patients being suitable for second-line
chemotherapy. Randomized trials formally comparing different
treatment algorithms in which first-, second- and even third-line
treatment choices are stipulated by the trial protocol may be
required to determine the optimal approach. Combination
chemotherapy unquestionably increases response rates, which may
have an important bearing on patients with limited metastatic
disease that might be amenable to surgical resection. 
Although currently only the subject of speculation, it may be
anticipated that improvements in response rates to neoadjuvant
chemotherapy may result in increased rates of long-term survival
following metastasectomy. For this reason complete response rates
to chemotherapy are becoming a more important end-point in
evaluating the efficacy of new combination regimens. At the present
time, the data supporting the use of a combination of 5-FU and
irinotecan in the first-line treatment of colorectal cancer is difficult to
resist. Such a combination approach is rapidly becoming standard
across North America for patients treated outside clinical trials.
Toxicity is increased over infused 5-FU regimens, but is similar to
that produced by the Mayo Clinic regimen of bolus 5-FU and folinic
acid, and does not impair quality of life. It is difficult to explain the
differing overall survival outcomes of the oxaliplatin and irinotecan
first-line combination studies in view of the very similar response
rates and time to tumour progression produced by either drug in
combination with 5-FU/folinic acid. A trial reported in preliminary
form earlier this year investigates the efficacy and toxicity of a
combination of irinotecan, 5-FU and folinic acid followed after
disease progression by a combination of oxaliplatin, 5-FU and folinic
acid. This is compared in a randomized fashion with the same two
combination regimens given in the reverse sequence (Tournigand
et al, 2000). The response rates to the first regimen in the two arms
are very high, and are equivalent (63% for the irinotecan combination
and 60% for the oxaliplatin combination). This trial may provide
evidence for the optimal order in which to give the available
active drugs. Until such evidence is available, other factors such
as the acceptability to the patient of the toxicity profile of the drug,
its convenience of administration and its cost are important
considerations (Table 4). 
The oral fluoropyrimidines and direct thymidylate synthase
inhibitors provide a substantial advance in the convenience of
chemotherapy administration. Preliminary data suggest that some
of these drugs can be administered safely in combination with
either irinotecan or oxaliplatin, and result in promising activity.
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Table 4 Comparison of oxaliplatin and irinotecan 
Oxaliplatin Irinotecan 
Toxicity
This drug has a well documented  As far as we are aware, no 
cumulative and only partially  irreversible toxicity 
reversible neurotoxicity
Diarrhoea and neutropenia occur  Diarrhoea and neutropenia occur 
but are less common than with  more commonly, but patient
irinotecan education and adherence to pro-
tocol lowers risk of severe toxicity 
No alopecia Alopecia common, but less frequent 
with 2-weekly schedules 
Pharmacy considerations
Administered as a 2-h infusion Administered as a 30-minute 
infusion 
Requires reconstitution prior to use No requirement for reconstitution 
Cost
The cost of these drugs appears 
roughly equivalent Combinations of oxaliplatin and irinotecan are also being eval-
uated and are the subject of an ongoing randomized North
American trial. Three drug regimens incorporating a fluoropyrim-
idine, oxaliplatin and irinotecan may also be feasible, and have the
potential to elevate response rates even further, although toxicity is
likely to be increased. Regimens in which irinotecan and oxali-
platin, each in combination with a fluoropyrimidine, are alternated
from cycle to cycle may overcome some of the toxicity problems
of the three-drug combination. This may also delay the onset of
oxaliplatin-induced neurotoxicity, which is related to the cumula-
tive exposure to this drug. An alternative approach is to tailor the
treatment regimen to the disease using molecular markers that
might predict sensitivity to individual agents. There is excellent
data to suggest that high thymidylate synthase expression within
the tumour predicts for poor response to 5-FU (Leichman et al,
1997; Salonga et al, 2000) or raltitrexed (Ford et al, 2000), and
topoisomerase I is being explored as a marker for sensitivity to
irinotecan. A caveat to this approach is that expression of these
enzymes can vary substantially between the primary tumour and
metastatic disease within the same patient. It follows that analysis
of biopsies of the metastatic tumour deposits is necessary to apply
this technology in a rational manner. A synthesis of these data is
presented in Figure 2 in the form of an algorithm for the treatment
of advanced colorectal cancer patients. 
The extensive experience that has been gained with the new
agents discussed above in the treatment of advanced colorectal
cancer is now being brought forward to the adjuvant setting. It is
likely that eradication of micrometastatic disease will be maximized
by using chemotherapy regimens with very high response rates in
patients with advanced disease. Standard 5-FU/folinic acid regi-
mens are being compared with combination regimens incorporating
oxaliplatin or irinotecan plus 5-FU/folinic acid in ongoing random-
ized trials in Europe and North America to test this hypothesis,
although the advances seen with combination chemotherapy in
metastatic disease are likely to be reflected in the adjuvant setting. 
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